@article{JGO24025,
author = {Joseph I. Kang and Daniel C. Sufficool and Chung-Tsen Hsueh and Andrew J. Wroe and Baldev Patyal and Mark E. Reeves and Jerry D. Slater and Gary Y. Yang},
title = {A phase I trial of Proton stereotactic body radiation therapy for liver metastases},
journal = {Journal of Gastrointestinal Oncology},
volume = {10},
number = {1},
year = {2018},
keywords = {},
abstract = {Background: A phase I trial to determine the maximum tolerated dose (MTD) of Proton stereotactic body radiation therapy (SBRT) for liver metastases in anticipation of a subsequent phase II study.
Methods: An institutional IRB approved phase I clinical trial was conducted. Eligible patients had 1–3 liver metastases measuring less than 5 cm, and no metastases location within 2 cm of the GI tract. Dose escalation was conducted with three dose cohorts. The low, intermediate, and high dose cohorts were planned to receive 36, 48, and 60 respectively to the internal target volume (ITV) in 3 fractions. At least 700 mL of normal liver had to receive },
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/24025}
}